ArticleFrontiers in microbiology2026
Establishment of a rapid detection method for severe fever with thrombocytopenia syndrome virus based on reverse transcription-recombinase polymerase amplification with lateral flow nucleic acid chromatography assay technology.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Severe fever with thrombocytopenia syndrome virus (SFTSV), a novel bunyavirus associated with febrile illness, thrombocytopenia, and leukopenia, represents a considerable public health threat. Methods: In this study, we developed a visual detection platform for SFTSV by integrating reverse transcription-recombinase polymerase amplification (RT-RPA) with lateral flow nucleic acid chromatography assay (LFNA). The method operates under isothermal conditions, and delivers results within 40 minutes. Using a conserved region of the S segment as the amplification target. Results: The assay demonstrated a detection limit of 10 Discussion: The RT-RPA-LFNA platform is easy to operate, provides rapid results and is cost-effective, and therefore has potential for use in point-of-care testing (POCT), particularly in resource-limited primary healthcare settings. This approach not only provides a reliable tool for SFTSV diagnosis but also holds potential for the detection of other pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.